Stemline Therapeutics (STML) Presents Strong SL-401 Phase 2 Data at ASH 2016; 100% ORR Noted
Tweet Send to a Friend
Stemline Therapeutics, Inc. (Nasdaq: STML) announced the oral presentation of positive clinical data from its ongoing SL-401 Phase 2 potentially ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
